Clinical trial NCT05529654: IMpella-Protected cArdiaC Surgery Trial (IMPACT)
Official title: IMpella-Protected cArdiaC Surgery Trial (IMPACT)
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Left Ventricular Dysfunction
Keywords: High-risk Cardiac Surgery
Low pre-operative left ventricular ejection fraction
Cardiopulmonary bypass (CPB)
Temporary Mechanical Circulatory System (MCS)
Lead sponsor: Abiomed Inc.
Sponsor class: INDUSTRY
First posted: 2022-09-07
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this Trial is to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients, with the overall aim to evaluate if using Impella 5.5 with SmartAssist (Impella 5.5) peri-operatively improves early hemodynamics, end-organ function and clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.

Detailed description: This is a prospective single-armed Trial to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients. A concurrent Registry will also be performed to collect information on patients meeting Exclusion Criteria and those not approached for enrollment. The overall aim is to evaluate if using Impella 5.5 peri-operatively improves early hemodynamics, end-organ function and subsequent clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.

Eligibility criteria: Inclusion Criteria:

1. Hemodynamically stable patients undergoing one of the following cardiac surgery procedures on CPB including aortic cross-clamping and cardioplegic arrest:

   * Isolated CABG
   * Isolated mitral valve repair or mitral valve replacement (MVR)
   * Isolated biological aortic valve replacement (AVR)
   * At least two of the following: CABG, MVR, AVR, or tricuspid valve repair or replacement (TVR)
   * Additional concomitant procedures permitted:

     1. Atrial septal defect (ASD) or patent foramen ovale (PFO) repair or closure
     2. Atrial fibrillation ablation procedures
     3. Left atrial ablation (all forms including complete left/right side Cox Maze)
     4. Coronary endarterectomy
2. LVEF within 30 days before surgery of either:

   * ≤25% measured by echocardiogram or cardiac MRI, OR
   * LVEF ≤35%, measured as above, for patients with significant mitral regurgitation (MR 3+ or 4+) and planned corrective mitral valve surgery (including MV replacement or repair)

     * Any subject with EF \<20% must have viability assessment performed to assess CABG candidacy (MRI preferred)
3. Age 18 years or older
4. Subject (or subject's LAR, if allowed by IRB) has signed Informed Consent Form

Exclusion Criteria:

1. Salvage operation (cardiac arrest within 24 hours prior to index surgery)
2. Unresponsive state within 24 hours of the time of surgery
3. Any inotrope within 72 hours of surgery
4. Any MCS device (such as IABP, ECMO, Impella®, CentriMag™ or TandemHeart®) in place at time of informed consent and less than 24 hours prior to index study procedure
5. RV dysfunction requiring mechanical or inotropic support pre-operatively and/or likely to be needed post-operatively
6. Index procedures requiring total circulatory arrest (TCA), such as aortic arch replacement, planned durable LVAD, durable RVAD, planned right-sided temporary mechanical support of any kind, total artificial heart (TAH), cardiac transplantation, pericardiectomy, pulmonary thromboendarterectomy and septal myectomy
7. Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade or other conditions in which cardiac output is dependent on venous return
8. Ventricular septal defect (VSD)
9. Stroke within 30 days of the index cardiac surgical procedure
10. Prior mantle field chest irradiation
11. Prior solid organ or hematologic transplantation (heart, kidney, liver, lung, pancreas, bone marrow) or durable LVAD
12. History of chronic dialysis
13. Pre-existing liver dysfunction defined as: Child-Pugh Class B or C
14. Pre-existing pulmonary disease requiring home oxygen or "severe pulmonary disease" determined by enrolling Investigator
15. Systemic active infection or evidence of systemic bacterial, fungal or viral infection within 72 hours before surgery (blood culture positive with leukocytosis)
16. Confirmed COVID-19 infection within two weeks prior to operation
17. Suspected or known pregnancy
18. Participation in the active treatment or follow-up phase of another interventional clinical trial of an investigational drug or device which has not reached its primary endpoint
19. Known contraindication to heparin; History of bleeding diathesis or known coagulopathy or will refuse blood transfusions
20. Inability to perform aortic cross-clamp, such as due to porcelain aorta
21. Any contraindication or inability to place Impella 5.5 (per the IFU), including LV thrombus and/or presence of a mechanical aortic valve
22. Any organ condition, concomitant disease (e.g., psychiatric illness, current severe alcoholism or current drug abuse, cancer, hepatic or kidney disease), with life expectancy of ≤2 years or other abnormality that itself or the treatment of which could interfere with the conduct of the trial or that, in the opinion of the investigator and/or Sponsor's medical monitor, would pose an unacceptable risk to the patient in the trial.
23. Patient has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with trial procedures
24. Patient belongs to a vulnerable population \[Vulnerable patient populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention\]

Primary outcomes:
measure: Composite of All-Cause Mortality
timeFrame: 90 days
measure: Stroke (as defined by STS)
timeFrame: 90 days
measure: New requirement for Renal Replacement Therapy (RRT)
timeFrame: 90 days
measure: Rate of Post-Cardiotomy Cardiac Failure
timeFrame: Hospital discharge, usually within 30 days
Secondary outcomes:
measure: Number of attempts to wean from CPB
timeFrame: Intra-op, usually within 1 day
measure: Duration of mechanical ventilation
timeFrame: ICU discharge, usually within 30 days
measure: Duration and dosages of inotropes and vasopressors. Duration of mechanical circulatory support (Hours)
timeFrame: ICU Discharge, usually within 30 days
measure: Acute Kidney Injury
timeFrame: within 7 days or at ICU Discharge (usually within 30 days)
measure: Vasoactive-inotropic score (VIS)
timeFrame: ICU Discharge, usually within 30 days
measure: Cardiovascular mortality
timeFrame: Hospital discharge, usually within 30 days
measure: Major Hemolysis
timeFrame: Hospital Discharge, usually within 30 days
measure: Major Vascular Complications
timeFrame: Hospital Discharge, usually within 30 days
measure: Major Bleeding
timeFrame: Hospital Discharge, usually within 30 days
measure: Length of ICU Stay
timeFrame: ICU Discharge, usually within 30 days
measure: Length of Hospital Stay
timeFrame: Hospital Discharge, usually within 30 days
measure: Quality of Life (QoL) assessed by KCCQ
timeFrame: 90 Days Post-Op
measure: Physical Activity
timeFrame: 90 Days Post-Op
measure: Technical Success
timeFrame: Intra-op, usually within 1 day
Other outcomes:
Locations:
city: Jonesboro
country: United States
facility: Cardiology Associates Research Group
state: Arkansas
city: Los Angeles
country: United States
facility: Keck School of Medicine
state: California
city: San Diego
country: United States
facility: Tri-City Medical Center
state: California
city: Aurora
country: United States
facility: University of Colorado
state: Colorado
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Naples
country: United States
facility: NCH Rooney Heart Institute
state: Florida
city: Atlanta
country: United States
facility: Emory University Hospital
state: Georgia
city: Boston
country: United States
facility: Mass General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Brigham & Women's
state: Massachusetts
city: Minneapolis
country: United States
facility: Minneapolis Heart Institute Foundation/Abbott Northwestern Hospital
state: Minnesota
city: Saint Louis
country: United States
facility: SSM Health Saint Louis University Hospital
state: Missouri
city: Saint Louis
country: United States
facility: Barnes-Jewish Hospital
state: Missouri
city: Hackensack
country: United States
facility: Hackensack University Medical Center
state: New Jersey
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
city: New York
country: United States
facility: NYU Langone Health
state: New York
city: New York
country: United States
facility: New York- Presbyterian Hospital/ Columbia University Medical Center
state: New York
city: Wilmington
country: United States
facility: New Hanover Regional Medical Center
state: North Carolina
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
city: Portland
country: United States
facility: Providence St. Vincent Medical Center
state: Oregon
city: Philadelphia
country: United States
facility: Hospital of The University of Pennsylvania
state: Pennsylvania
city: Nashville
country: United States
facility: Centennial Heart Cardiovascular
state: Tennessee
city: Austin
country: United States
facility: University of Texas Austin Dell Medical School/Ascension Texas
state: Texas
city: Plano
country: United States
facility: Baylor Scott and White - Plano
state: Texas
Study officials:
affiliation: Montefiore Medical Center
name: Daniel Goldstein, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: The Cleveland Clinic
name: Edward Soltesz, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Heart & Vascular Center Hamburg
name: Hermann Reichenspurner, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: